IRS1
ENSG00000169047
Target class
Unclassified protein
Chromosome
2
- Chemical probe available
- No
- Other names
- HIRS-1
- Target name
- IRS1
- Gene name
- Insulin receptor substrate 1
- Gene symbol
- IRS1
- Protein name
- Insulin receptor substrate 1 (IRS-1)
- Gene biotype
- Protein coding
- Gene family
- Pleckstrin homology domain containing
- Target class
- Unclassified protein
- Target type
- Human gene
- Tissues expressed in
- 51
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 50.34
- Tissue specificity (Gini)
- 0.542
- Tissue specificity (tau)
- 0.803
- KEGG gene identifiers
- hsa:3667
- Protein interaction confidence
- 0.866081
- Protein interaction partners
- 123
- R-HSA-109704
- R-HSA-112399
- R-HSA-112412
- R-HSA-1257604
- R-HSA-1266695
- R-HSA-198203
- R-HSA-201556
- R-HSA-2219530
- R-HSA-2428928
- R-HSA-2586552
- R-HSA-5673001
- R-HSA-6811558
- R-HSA-74713
- R-HSA-74749
- R-HSA-9603381
- R-HSA-9725370
- R-HSA-982772
- R-HSA-9842663
- End position
- 226799820
- Start position
- 226731312
- Chromosome
- 2
- Strand
- Reverse
- Cytoplasm . Nucleus . Note=Nuclear or cytoplasmic localization of IRS1 correlates with the transition from proliferation to chondrogenic differentiation. .
- Cytosol
- Nucleoplasm
- Plasma membrane
- Vesicles
Publication evidence
- PubMed 19639489
- Tissue specificity (tau)
- 0.803412
- Expression inequality (Gini)
- 0.542164
Expression in transcripts per million
- Cells - Cultured fibroblasts
- 50.34
- Cervix - Endocervix
- 43.16
- Ovary
- 42.29
- Fallopian Tube
- 41.62
- Thyroid
- 37.36
Expression in transcripts per million
- Cells - Cultured fibroblasts50.34
- Cervix - Endocervix43.16
- Ovary42.29
- Fallopian Tube41.62
- Thyroid37.36
- Uterus31.33
- Bladder23.89
- Colon - Sigmoid19.3
- Cervix - Ectocervix18.77
- Prostate15.35
- Breast - Mammary Tissue14.66
- Vagina14
- Esophagus - Muscularis12.91
- Artery - Tibial11.35
- Adrenal Gland10.67
- Adipose - Subcutaneous10.62
- Lung10.59
- Nerve - Tibial9.98
- Esophagus - Gastroesophageal Junction9.92
- Artery - Aorta9.76
- Skin - Not Sun Exposed (Suprapubic)9.06
- Skin - Sun Exposed (Lower leg)8.7
- Adipose - Visceral (Omentum)8.65
- Colon - Transverse8.38
- Brain - Cerebellar Hemisphere8.35
And 29 more, listed on the interactive page.
- GO:0007165
- GO:0008286
- GO:0010907
- GO:0019221
- GO:0032000
- GO:0032868
- GO:0032869
- GO:0042593
- GO:0043491
- GO:0045725
- GO:0046326
- GO:0046628
- GO:0046676
- GO:0048009
- GO:0005634
- GO:0005737
- GO:0005829
- GO:0005886
- GO:0005901
- GO:0001784
- GO:0005068
- GO:0005158
- GO:0005159
- GO:0005515
- GO:0030159
- GO:0035591
- GO:0043548
Related records
Trials (3)
- A Phase 1 Clinical Study Comparing GS101 and Dupixent® After Subcutaneous Injection
- A Phase III Study of GS101 Injection to Dupixent®
- Trial of Aganirsen in iCRVO Patients at Risk of Developing NVG
Drugs (1)
- Aganirsen Insulin receptor substrate 1 mRNA antisense inhibitor